Vivani Medical (VANI) Projected to Post Quarterly Earnings on Monday

Vivani Medical (NASDAQ:VANI) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Vivani Medical to post earnings of ($0.10) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

Vivani Medical Price Performance

NASDAQ:VANI opened at $1.16 on Monday. The firm has a market capitalization of $90.68 million, a P/E ratio of -2.58 and a beta of 3.17. The business has a 50 day simple moving average of $1.27 and a 200 day simple moving average of $1.36. Vivani Medical has a 12-month low of $0.91 and a 12-month high of $1.92.

Insiders Place Their Bets

In related news, Director Gregg Williams acquired 1,575,231 shares of Vivani Medical stock in a transaction that occurred on Sunday, March 15th. The stock was acquired at an average price of $1.07 per share, with a total value of $1,685,497.17. Following the completion of the acquisition, the director directly owned 31,357,183 shares of the company’s stock, valued at $33,552,185.81. This trade represents a 5.29% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 4,664,347 shares of company stock valued at $5,666,549 over the last three months. Corporate insiders own 46.40% of the company’s stock.

Institutional Trading of Vivani Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in shares of Vivani Medical in the 3rd quarter worth approximately $26,000. Susquehanna International Group LLP raised its holdings in Vivani Medical by 100.5% during the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares in the last quarter. Jane Street Group LLC acquired a new stake in Vivani Medical in the fourth quarter worth approximately $60,000. Renaissance Technologies LLC boosted its stake in Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Vivani Medical during the 4th quarter valued at $174,000. 6.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.